

Cesar Jimenez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8356528/publications.pdf>

Version: 2024-02-01

9
papers

607
citations

1684188

5
h-index

1588992

8
g-index

9
all docs

9
docs citations

9
times ranked

667
citing authors

#	ARTICLE	IF	CITATIONS
1	Severity of gastrointestinal bleeding is similar between patients receiving direct oral anticoagulants or vitamin K antagonists. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.3	2
2	Effect of rifaximin on infections, acute and chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-ACH). <i>Liver International</i> , 2022, 42, 1109-1120.	3.9	20
3	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1100-1112.	4.3	5
4	Value of pilot studies in alcohol-associated hepatitis. <i>Liver International</i> , 2022, 42, 1697-1697.	3.9	0
5	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
6	The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110165.	3.2	7
7	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673.	7.3	67
8	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	8.1	75
9	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282